Combinatorial pharmacogenomic (CPGx™) GeneSight method predicts healthcare outcomes better than traditional, single-gene analysis.
“Multigenic combinatorial testing discriminates and predicts the poorer antidepressant outcomes and greater health-care utilizations by depressed subjects better than do phenotypes derived from single genes.”
Altar CA, et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J 2015; 15:443-51.
Learn More View Article